Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase.
A series of analogs of the potent HIV-1 integrase (HIV IN) inhibitor chicoric acid (CA) was designed with the intention of ameliorating some of the parent natural product's undesirable properties, in particular its toxicity, instability, and poor membrane permeability. More than 70 analogs were synthesized and assayed for three types of activity: (1) the ability to inhibit 3'-end processing and strand transfer reactions using recombinant HIV IN in vitro, (2) toxicity against the CD4+ lymphoblastoid cell line, MT2, and (3) anti-HIV activity against HIV(LAI). CA analogs lacking one of the carboxyl groups of CA and with 3,4,5-trihydroxycinnamoyl sidechains in place of the caffeoyl group of CA exhibited the most potent inhibition of HIV replication and end-processing activity. Galloyl-substituted derivatives also displayed very potent in vitro and in vivo activities, in most cases exceeding the inhibitory effects of CA itself. Conversely, analogous monocarboxy caffeoyl analogs exhibited only modest inhibition, while the corresponding 3,4-dihydroxybenzoyl-substituted compounds were devoid of activity.
Charvat
Trevor T
TT
Department of Chemistry, University of California, Irvine, 92697, USA.
Lee
Deborah J
DJ
Robinson
W Edward
WE
Chamberlin
A Richard
AR
D019380:Anti-HIV Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002109:Caffeic Acids / Q000737:chemistry*; D045744:Cell Line, Tumor; D002462:Cell Membrane; D015195:Drug Design; D006678:HIV / Q000187:drug effects; D019428:HIV Integrase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D006801:Humans; D011995:Recombination, Genetic / Q000187:drug effects; D013386:Succinates / Q000737:chemistry*
D019380:Anti-HIV Agents; D002109:Caffeic Acids; D019428:HIV Integrase Inhibitors; D013386:Succinates; C100435:chicoric acid